Daan de Lange
Daan de Lange is a partner at Brinkhof specialising in international patent disputes, with a primary focus on pharma and biotech cases in which Daan acts for both innovative and generic parties. He also specialises in international FRAND litigation, in which he mainly represents mobile phone manufacturers.
Complex, demanding and international disputes
Daan is a true litigator who excels in complex, demanding, and international disputes. He is described by IAM Patent 1000 as “a brilliant lawyer who is tremendously gifted in patent law. He has a unique talent of turning around unwinnable patent disputes and coming out successful.” Daan’s clients value him for his direct and clear advice, as well as his strategic insight.
What others say about Daan:
“He has a bright mind, is easy to work with and also really digs into the matter.” (Chambers Global 2023)
Experience & ancillary activities
Daan is the editor of the IP journal BIE and regularly publishes on patent law. He is also a lecturer at the Professional Course for Patent Attorneys. Daan is a sought-after speaker at conferences and an active member of professional associations such as EPLAW and AIPPI. He is deeply involved in the development of the Unified Patent Court (UPC) and keeps his clients up to date on the latest developments in that field.
Some of the cases Daan de Lange has handled:
- in Amgen v Sanofi, Daan represented Amgen in a dispute concerning Amgen’s PCSK9 inhibitor Repatha®;
- representing Sandoz in several high-profile cases, including in connection with the blood thinner rivaroxaban;
- in Xiaomi v Sisvel (FRAND), Daan successfully defended Xiaomi against infringement claims brought by Sisvel. These proceedings were named “Impact Case of the Year” by Managing IP in 2021;
- in Oppo v Nokia (FRAND), Daan managed to fend off an injunction claim in summary proceedings on behalf of Oppo.